Bristol Myers Squibb Company $BMY Stock Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 17.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 418,780 shares of the biopharmaceutical company’s stock after selling 89,960 shares during the period. Jefferies Financial Group Inc.’s holdings in Bristol Myers Squibb were worth $26,132,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Davis Investment Partners LLC increased its holdings in shares of Bristol Myers Squibb by 23.7% during the 3rd quarter. Davis Investment Partners LLC now owns 19,024 shares of the biopharmaceutical company’s stock worth $1,187,000 after acquiring an additional 3,643 shares during the last quarter. Illinois Municipal Retirement Fund lifted its holdings in Bristol Myers Squibb by 4.2% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 778,865 shares of the biopharmaceutical company’s stock valued at $48,601,000 after purchasing an additional 31,723 shares during the last quarter. Mesirow Financial Investment Management Inc. lifted its holdings in Bristol Myers Squibb by 5.6% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 33,807 shares of the biopharmaceutical company’s stock valued at $2,110,000 after purchasing an additional 1,784 shares during the last quarter. Lido Advisors LLC boosted its position in Bristol Myers Squibb by 20.9% during the third quarter. Lido Advisors LLC now owns 145,914 shares of the biopharmaceutical company’s stock worth $9,105,000 after purchasing an additional 25,193 shares during the period. Finally, Cornerstone Wealth Management LLC boosted its position in Bristol Myers Squibb by 2.6% during the third quarter. Cornerstone Wealth Management LLC now owns 35,552 shares of the biopharmaceutical company’s stock worth $2,218,000 after purchasing an additional 896 shares during the period. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on BMY shares. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Leerink Partners cut shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $73.00 to $59.00 in a research note on Monday, October 5th. TD Cowen began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating for the company. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. Finally, Zacks Research downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $65.46.

Insider Transactions at Bristol Myers Squibb

In other news, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Up 0.2%

BMY opened at $62.91 on Thursday. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The company has a market capitalization of $128.59 billion, a P/E ratio of 13.95, a P/E/G ratio of 0.32 and a beta of 0.20. The stock has a fifty day moving average of $62.09 and a 200-day moving average of $60.23.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same quarter in the previous year, the business posted $1.63 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 6.9% on a year-over-year basis. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.45 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb’s payout ratio is 55.88%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.